Cd33 specific chimeric antigen receptors
AssigneeIntrexon Corporation
InventorsRutul Shah, Tim Chan, Peter Emtage, Ramya Yarlagadda
Life of this patent
Estimating the term…
Abstract
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.
Claims36
-13. (canceled)
A vector comprising a backbone and a nucleic acid sequence encoding:
- (1) a truncated epidermal growth factor receptor comprising at least one of HER1t, HER1t-1 or a functional variant thereof;
- and
- (2) a chimeric antigen receptor (CAR), wherein the CAR comprises
- (a) a CD33 antigen binding domain;
- (b) a stalk domain;
- (c) a transmembrane domain;
- (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both;
- and
- (e) a CD3 zeta signaling domain.
(canceled)
-23. (canceled)
-26. (canceled)
(canceled)
-33. (canceled)
(canceled)
An immune effector cell comprising a vector comprising a backbone and a nucleic acid sequence encoding
- (1) a truncated epidermal growth factor receptor (HER1t);
- and
- (2) chimeric antigen receptor (CAR), wherein the CAR comprises
- (a) a CD33 antigen binding domain;
- (b) a stalk domain;
- (c) a transmembrane domain;
- (d) a costimulatory signaling domain comprising 4-1BB or CD28, or both;
- and
- (e) a CD3 zeta signaling domain.
(canceled)
(canceled)
A method for stimulating a T cell-mediated immune response to a target cell population or tissue in a human subject in need thereof, comprising administering to said human subject an effective amount of a cell genetically modified to express a CAR, wherein the CAR comprises
- (a) a CD33 antigen binding domain;
- (b) a stalk domain;
- (c) a transmembrane domain;
- (d) a costimulatory signaling domain comprising 4-1 BB or CD28, or both;
- (e) a CD3 zeta signaling domain;
- and
- (f) a truncated epidermal growth factor receptor (HER It).
-52. (canceled)
-66. (canceled)
-73. (canceled)
Dependencies are inferred from the claim text.